Last reviewed · How we verify
GD007 Low-dose drug group — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GD007 Low-dose drug group (GD007 Low-dose drug group) — The First Affiliated Hospital with Nanjing Medical University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GD007 Low-dose drug group TARGET | GD007 Low-dose drug group | The First Affiliated Hospital with Nanjing Medical University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GD007 Low-dose drug group CI watch — RSS
- GD007 Low-dose drug group CI watch — Atom
- GD007 Low-dose drug group CI watch — JSON
- GD007 Low-dose drug group alone — RSS
Cite this brief
Drug Landscape (2026). GD007 Low-dose drug group — Competitive Intelligence Brief. https://druglandscape.com/ci/gd007-low-dose-drug-group. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab